LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc.

LifeSci Advisors Initiates Coverage of Cancer Genetics, Inc. 
Strong Portfolio of Unique Genomic Diagnostic Tests for Personalized
Medicine in Oncology; Consistent Revenue and Gross Profit Growth;
$6.6 Million in 2013 Revenue; Report Available for Download at
http://www.lifesciadvisors.com/clients/cancergenetics/ 
NEW YORK, NY -- (Marketwired) -- 04/01/14 --   LifeSci Advisors, LLC,
a leading provider of investment research and investor relations
services in the life sciences sector, today announced that it has
initiated coverage of Cancer Genetics, Inc. (NASDAQ: CGIX), a
diagnostics company developing genomic-based oncology tests and
services to enhance disease management and patient outcomes. The
Company offers a wide-range of proprietary and non-proprietary tests
to support patients during all aspects of their care, from initial
diagnosis to prognosis, and determination of optimal treatment
options. Oncology is moving towards categorizing cancers by their
molecular signature rather than the location in the body, and there
is a continuing need for wider access to diagnostic toolkits. Cancer
Genetics collaborates with leading research institutions for
biomarker development, with community hospitals to improve patient
care, and with biotechnology and pharmaceutical companies to provide
clinical trial services.  
"Cancer Genetics couples its expertise identifying genetic
aberrations with recommendations for patient prognosis and treatment,
generating a personalized therapeutic plan for each patient," said
Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors.
"This level of focus on the patient has led to key partnerships with
Gilead and Roche, and sets the stage for continued integration into
the pursuit of personalized medicine in oncology." 
Cancer Genetics has five unique tests that are approved by New York
State and Clinical Laboratory Improvement Amendments (CLIA) for
leukemia, lymphomas, renal and cervical cancer. Mature B-cell
Neoplasm Array (MatBA(R)) is a genomic hybridization array for the
diagnosis and prognosis of non-Hodgkin lymphomas. UroGenRA(TM) is a
genomic hybridization array for the classification of urogenital
cancers, and FISH-based HPV-Associated Cancer Test (FHACT(TM)) is a
platform for HPV-associated cervical cancer screening. Additional
indications are being pursued for each platform.  
Cancer Genetics has deals in place with Gilead Sciences, Inc. and
Roche Servicios S.A., a Costa Rica-based subsidiary of Roche. The
partnerships are a validation of the Cancer Genetics' ability to
secure the necessary relationships to become the market leader in
diagnostics. Additionally, Cancer Genetics continues to invest in
developing further technology by leveraging next-generation
sequencing in a joint venture with Mayo Clinic that is focused on
developing panels for oncology indications in lung cancer, follicular
lymphoma, and multiple myeloma. 
In a 35 page Initiation Report by LifeSci Advisors, we explain the
products and services offered by Cancer Genetics and how the Company
intends to continue expanding revenues. The report discusses the
three proprietary technology platforms and the indications they
target. We also explore the market potential and competitive
landscape for molecular diagnostics going forward.  
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, www.lifesciadvisors.com. In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur. 
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-Head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
Cytokinetics. 
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
website, www.lifesciadvisors.com.  
Important Disclosures: 
The research report described in this press release is not intended
as an offering, recommendation, or a solicitation of an offer to buy
or sell securities. The securities discussed in LSA research reports
may be unsuitable for some investors depending on their specific
investment objectives, financial status, risk profile, or particular
needs. Investors should consider LSA reports as only a single factor
in making their investment decisions and should not rely solely on
these reports in evaluating whether or not to buy or sell the
securities of the subject company. LifeSci Advisors has been
compensated by the company that is the subject of the report
described and future research reports, investor relations services,
and general consulting services. Please read each report's full
disclosures and analyst background on the LSA website,
www.lifesciadvisors.com, before investing. LifeSci Advisors is not a
registered investment adviser or broker-dealer.  
Forward-looking statements: 
This press release contains forward-looking statements subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. These forward-looking statements
represent LSA's judgment as of the date of this release. LifeSci
Advisors disclaims, however, any intent or obligation to update these
forward-looking statements. 
Media Contact:
Michael Rice
Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com 
 
 
Press spacebar to pause and continue. Press esc to stop.